---
name: Halix
slug: halix
site: cdmo
website_domain: halix.nl
summary: HALIX is a mammalian expression CDMO specializing in viral vectors, viral vector vaccines, and recombinant proteins from development through GMP manufacturing and fill-finish at clinical and commercial scale. Headquartered in Leiden, Netherlands.
tagline: Mammalian CDMO for viral vectors, vaccines, and recombinant proteins from development to commercial GMP manufacturing.
founded_year: 2012
employee_count_band: 
employee_count_label: 
parent_name: 
parent_slug: 
hq_country: NL
tier2_domain_verified: false
updated_at: 2026-09-27T07:01:09.036Z
services_count: 14
modalities_count: 3
indications_count: 3
locations_count: 1
review_signal_gate: closed
generated_by: BioBM Editorial AI
---

# Halix

Mammalian CDMO for viral vectors, vaccines, and recombinant proteins from development to commercial GMP manufacturing.

Listed on cdmo.directory.

## Summary

HALIX is a mammalian expression CDMO specializing in viral vectors, viral vector vaccines, and recombinant proteins from development through GMP manufacturing and fill-finish at clinical and commercial scale. Headquartered in Leiden, Netherlands.

## At a glance

- Founded: 2012
- HQ country: NL

## Services

- Upstream Processing
- Downstream Processing
- Recombinant Protein Manufacturing
- Monoclonal Antibody (mAb) Manufacturing
- Viral Vector Manufacturing
- Vaccine Manufacturing
- Sterile Fill-Finish & Aseptic Manufacturing
- Lyophilization (Freeze Drying)
- Vial Filling
- Quality Control Testing
- Process Development
- Technology Transfer
- CMC Regulatory Submission Support
- Secondary Packaging & Labeling

## Modalities

- Vaccine
- Biologics (Monoclonal Antibodies)
- Biologics (Other)

## Indications

- Oncology
- Infectious Disease
- Respiratory

## Locations

- Headquarters & Manufacturing, Leiden, South Holland, Netherlands

## Certifications

- EMA; Identifier: EU GMP Grade C and Grade B; Source: https://halix.nl/

## Long description

## Overview

HALIX is a contract development and manufacturing organization (CDMO) focused on mammalian expression systems for viral vectors, viral vector vaccines, and recombinant proteins. Established in 2012 as a spin-off of HAL Allergy, the company combines decades of GMP expertise with startup agility to support biotech and pharma partners from development through commercial production.

## Facility & Infrastructure

Located in the Leiden Bio Science Park in the Netherlands, HALIX operates a 6,700 m² facility built in 2019 with:

- 10 clean rooms ("box in box" design)
- 7 bioreactors with upstream processing capacity up to 1,000 L scale
- EU GMP Grade C production suites for drug substance manufacturing
- EU GMP Grade B production suites for drug product manufacturing
- Independent air treatment per clean room suite
- Continuous GMP monitoring systems
- BSL2 containment with potential upgrade to BSL3
- Design compliant with EMA/FDA guidelines

## Core Capabilities

**Viral Vector & Vaccine Manufacturing:**
- Experience with AAV, Adenovirus, and Influenza virus
- Transient transfection expertise for accelerated timelines
- Aseptic fill and finish and lyophilization of viruses (BSL2)

**Recombinant Protein Manufacturing:**
- Monoclonal antibodies, bispecific antibodies, biosimilars, and recombinant proteins
- Adherent and suspension cell line experience
- Purification via depth filtration, tangential flow filtration (TFF), and chromatography
- Single-use disposable equipment

**Fill & Finish:**
- Small and large scale aseptic filling up to 20,000 vials
- Lyophilization of proteins, peptides, vaccines, allergens, small molecules, and viruses
- Labeling and packaging with custom layouts and randomization

**Complementary Services:**
- Full QC services with in-house qualified persons for batch release
- QP batch release and certification of GMP manufactured batches
- Regulatory support (pre-clinical, clinical, and commercial)
- Long-stay storage and replenishment of commercial drug products
- Reformulation for new dose forms or strengths

## Track Record

HALIX has delivered commercial AstraZeneca COVID-19 vaccine manufacturing and serves over 75 customers in both clinical and commercial stages with a 90% retention rate. Notable partnerships include NovalGen (NVG-111 clinical supply in under seven months), Rocketvax (VIRUFLEX™ platform), and Xenikos (T-Guard® aseptic fill and finish).

## Corporate Structure

HALIX is a 100% subsidiary of HAL Allergy Holding B.V., which is part of the family-owned Droege Group AG, providing long-term financial stability and investment opportunity.

## Related companies

- [Boston Institute of Biotechnology, LLC](/companies/bostonbib) (Upstream Processing, Downstream Processing) — [Compare](/compare/bostonbib/halix)
- [FUJIFILM Biotechnologies](/companies/fujifilm-biotechnologies) (Upstream Processing, Downstream Processing) — [Compare](/compare/fujifilm-biotechnologies/halix)
- [Samsung Biologics](/companies/samsungbiologics) (Upstream Processing, Downstream Processing) — [Compare](/compare/halix/samsungbiologics)
- [Yapan Bio](/companies/yapan-bio) (Upstream Processing, Downstream Processing) — [Compare](/compare/halix/yapan-bio)
- [National Resilience](/companies/resilience) (Upstream Processing, Downstream Processing) — [Compare](/compare/halix/resilience)
- [WuXi Vaccines](/companies/wuxivaccines) (Upstream Processing, Downstream Processing) — [Compare](/compare/halix/wuxivaccines)
- [Cytovance Biologics](/companies/cytovance-biologics) (Upstream Processing, Downstream Processing) — [Compare](/compare/cytovance-biologics/halix)
- [Grand River Aseptic Manufacturing](/companies/grandriverasepticmfg) (Monoclonal Antibody (mAb) Manufacturing, Vaccine Manufacturing) — [Compare](/compare/grandriverasepticmfg/halix)

_Profile last updated: 2026-09-27T07:01:09.036Z. Profile facts may include AI-assisted enrichment._

Auto-generated by BioBM Editorial AI for machine-readable profile access.